Ovarian Cancer Therapy Sales will reach $1.71bn in 2019, a new visiongain study predicts

LONDON - Oct. 22, 2015 - PRLog -- PHA0059 Press release text for Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025 – Recently Approved Treatments Give High Market Potential

Ovarian cancer therapy sales will reach $1.71bn in 2019, a new visiongain study predicts

A new report by visiongain forecasts the overall world market for drugs treating cancer of the ovaries will reach $1.71 billion in 2019. That revenue prediction and others appear in Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025 – Recently Approved Treatments Give High Market Potential, published in July 2015.

The purpose of that investigation is to show forecasts and qualitative analyses of the ovarian cancer therapy market, explaining its technological and commercial potentials. Visiongain is a business information publisher and consultancy in London, UK. It produces analyses to help organisations understand prospects of industries and markets.

That new studyanalyses the ovarian cancer therapy market’s results in 2014, as well as forecasting its prospects for revenue growth from 2015 to 2025. In particular, the work examines three leading products on the market, which are currently the only treatments with patent protection. The report provides revenue forecasts for each, as well as the overarching market and its segments.

Visiongain finds the ovarian cancer treatments market, which was once dominated by generics, is evolving as new drugs enter the market and promising pipeline candidates enter late stage development. Opportunities for pharmaceutical companies open up, giving high sales potentials. The study finds the market will expand, driven by the growing patient population and rising costs of drug therapies.

Alyscia Curtis, a senior pharmaceutical industry analyst in visiongain, said: “The world market for ovarian cancer treatments has become dominated by generic chemotherapies following patent expiries for leading drugs almost 15 years ago. The market has seen new approvals in recent years, such as Yondelis, Avastin and Lynparza, which are gradually capturing market share.

“The industry is changing, and novel therapies are in development. However, the success of these agents will depend on how much of an improvement they provide over the current standard of care. This is particularly of importance for cost-effectiveness assessments, which are having a greater impact on the industry as healthcare budgets are tightened. With a growing incidence of ovarian cancer and high recurrence and mortality rates, the demand for better treatment will continue to bolster that drug market.”

Visiongain’s new analysisshows revenue forecasts to 2025 at overall world market, submarket, product (brand) and national level. First it gives revenue predictions to 2025 for four therapeutic submarkets at world level:

·         Chemotherapy

·         Targeted therapies

·         Immunotherapy

·         Hormonal treatments.

That study then predicts ovarian cancer revenues of Avastin (bevacizumab), Lynparza (olaparib) and Yondelis (trabectedin) to 2025.

Research, data and analyses cover activities of Roche, AstraZeneca, Johnson & Johnson, Zeltia, Chugai and other developers, manufacturers and marketers of ovarian cancer therapies.

That new study discusses R&D and commercial news. It also shows three research interviews with Prima BioMed, OXiGENE and VBL Therapeutics. Details of over 50 pipeline products appear. The report also forecasts revenues to 2025 in 11 leading national markets:

·         United States (US)

·         Japan

·         Germany, France, the United Kingdom (UK), Italy and Spain (EU5 group)

·         Brazil, Russia, India and China (BRIC countries).

Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025 adds to visiongain’s analyses on industries and markets in healthcare. Together those studies cover pharmaceuticals, diagnostics, medical devices, outsourced services and biotechnologies.